These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Kurz SC; Zan E; Cordova C; Troxel AB; Barbaro M; Silverman JS; Snuderl M; Zagzag D; Kondziolka D; Golfinos JG; Chi AS; Sulman EP Clin Cancer Res; 2024 Feb; 30(4):680-686. PubMed ID: 38048045 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic analysis of [ Bashir A; Vestergaard MB; Binderup T; Broholm H; Marner L; Ziebell M; Fugleholm K; Mathiesen T; Kjær A; Law I Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2577-2588. PubMed ID: 32170347 [TBL] [Abstract][Full Text] [Related]
9. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients. Cleary JO; Yeung J; McMeekin H; Wilhelm T; Wagner T Nucl Med Commun; 2016 Nov; 37(11):1197-205. PubMed ID: 27399848 [TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor imaging with [ Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275 [TBL] [Abstract][Full Text] [Related]
11. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy. Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355 [TBL] [Abstract][Full Text] [Related]
12. The usefulness of [ Wang P; Liu S; Li X; Liu X; Li S; Wu Z; Cheng X Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):218-225. PubMed ID: 37682301 [TBL] [Abstract][Full Text] [Related]
13. PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study. Wang H; Hou B; Lu L; Feng M; Zang J; Yao S; Feng F; Wang R; Li F; Zhu Z J Nucl Med; 2018 Mar; 59(3):523-528. PubMed ID: 28775202 [TBL] [Abstract][Full Text] [Related]
15. Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication. Dressen MS; Muthukrishnan A; Tragon TR; Lieberman FS; Mountz JM Clin Nucl Med; 2019 Jan; 44(1):e26-e27. PubMed ID: 30371576 [TBL] [Abstract][Full Text] [Related]
16. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms. Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939 [TBL] [Abstract][Full Text] [Related]
17. DOTATATE PET/MR Imaging Differentiates Secondary-Progressive from de Novo World Health Organization Grade 3 Meningiomas. Kim JT; Chang SJC; Haghdel A; Ramakrishna RR; Pannullo SC; Schwartz TH; Osborne JR; Magge RS; Fine HA; Cisse B; Stieg P; Lin E; Roytman M; Palmer JD; Karakatsanis NA; Pisapia D; Liechty B; Knisely JPS; Ivanidze J AJNR Am J Neuroradiol; 2024 Jun; 45(6):773-780. PubMed ID: 38604734 [TBL] [Abstract][Full Text] [Related]